Paris IBD Center S.A.S.

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Ulcerative colitis3 trials
• Crohn's disease2 trials

Phase

• Phase 24 trials

Status

• Completed4 trials

Lead sponsor

• Amgen Inc.2 trials
• Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)2 trials

Closed trials

• Completed

  Long-term Safety and Efficacy of Efavaleukin Alfa in Subjects With Moderately to Severely Active Ulcerative Colitis

  NCT05672199· Phase 2· Amgen Inc.· Source

• Completed

  Safety and Efficacy of Efavaleukin Alfa in Subjects with Moderately to Severely Active Ulcerative Colitis

  NCT04987307· Phase 2· Amgen Inc.· Source

• Completed

  A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

  NCT05013905· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Completed

  A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)

  NCT04996797· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source